Compare INSM & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | A |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 39.8B |
| IPO Year | 2000 | 1999 |
| Metric | INSM | A |
|---|---|---|
| Price | $163.99 | $136.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 16 |
| Target Price | ★ $187.30 | $165.13 |
| AVG Volume (30 Days) | ★ 3.9M | 2.0M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 4.57 |
| Revenue | $447,022,000.00 | ★ $6,948,000,000.00 |
| Revenue This Year | $49.51 | $8.02 |
| Revenue Next Year | $134.47 | $6.28 |
| P/E Ratio | ★ N/A | $30.56 |
| Revenue Growth | ★ 30.34 | 6.73 |
| 52 Week Low | $60.40 | $96.43 |
| 52 Week High | $212.75 | $160.27 |
| Indicator | INSM | A |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 36.25 |
| Support Level | $168.01 | $143.14 |
| Resistance Level | $186.74 | $150.10 |
| Average True Range (ATR) | 6.81 | 3.69 |
| MACD | -0.81 | -0.37 |
| Stochastic Oscillator | 25.51 | 5.24 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.